Bausch + Lomb Corporation

NYSE:BLCO

Medical - Instruments & Supplies

Healthcare
$20.95 +0.27%

+$0.04 today

Market cap
$7.49B
Beta
0.57
P/E (TTM)
-24.2
EPS (TTM)
-$0.62
52W Low $11.58High $18.92

Volume 0.51M

Average 0.46M

BLCO Interest Income

Income earned on cash, deposits, and investments held by the company.

Bausch + Lomb CorporationNYSE: BLCO

Interest Income · Q2 FY2026 · quarter ended Jun 2026

Interest income growth accelerates

Q2 FY2026 interest income of $4M rose 33.3% year over year, ahead of the -6.7% change in trailing-twelve-month interest income. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +26.0% a year.

Context

  • Interest income amounted to 0.2% of revenue in FY2025, unchanged from a year earlier.
  • Interest income increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +33.3% holds above the trailing-twelve-month pace of -6.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$4M+0.0% QoQ
Last fiscal yearDec 2025
$12M-20.0% YoY
LTMJun 2026
$14M-6.7% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+33.3%——
1 year-20.0%——
3-year CAGR+26.0%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
12M USD
Year-over-year change
-20.0%

Interest Income vs competitors

How BLCO compares with its peers on the latest reported figures

  • BLCO's LTM Jun 2026 interest income of $14M is the 4th highest of the 10 companies compared; the peer median is $7.14M.
  • Its year-over-year change of -6.7% is the 3rd highest of 6, against a peer median of -9.9%.
  • Interest income amounts to 0.3% of revenue for BLCO, versus a peer median of 0.1%.
BLCO Competitors Peer median
Interest Income for BLCO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PCVXVaxcyte, Inc.LTM Jun 2026$108.08M -15.9%+142.9%—
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$57.86M +55.2%+55.8%12.8%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$15.68M -1.4%+225.0%1.0%
BLCOBausch + Lomb CorporationLTM Jun 2026$14M -6.7%+26.0%0.3%
GKOSGlaukos CorporationLTM Jun 2026$9.77M -9.9%+65.2%1.6%
TFXTeleflex IncorporatedLTM Jun 2026$7.14M -12.0%+91.5%0.3%
TGTXTG Therapeutics, Inc.LTM Sep 2026$0 ——0.0%
OSCROscar Health, Inc.LTM Jun 2026$0 ——0.0%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$0 ——0.0%
CRSPCRISPR Therapeutics AGLTM Sep 2026$0 ——0.0%
Peer median (excluding BLCO) $7.14M-9.9%+91.5%0.1%

Competitors are the stored peer set for BLCO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.77B3.77B4.15B4.79B5.1B
Cost of Revenue1.47B1.52B1.64B1.87B2.31B
Gross Profit2.3B2.25B2.5B2.92B2.79B
Gross Margin61.0%59.7%60.4%60.9%54.8%
Research & Development271M307M324M343M371M
Selling, General & Admin1.39B1.48B1.74B2.08B2.23B
Operating Expenses1.97B2.04B2.37B2.76B2.61B
Depreciation & Amortization415M379M382M436M421M
EBITDA733M598M499M601M535M
EBITDA Margin19.5%15.9%12.0%12.5%10.5%
Operating Income329M207M130M162M188M
Operating Margin8.7%5.5%3.1%3.4%3.7%
Interest Income06M15M15M12M
Interest Expense0146M283M399M431M
Other Income / Expenses(11M)(134M)(296M)(396M)(505M)
Income Before Tax318M73M(166M)(234M)(317M)
Pre-Tax Margin8.4%1.9%-4.0%-4.9%-6.2%
Income Tax Expense125M58M82M71M35M
Net Income182M6M(260M)(317M)(360M)
Net Margin4.8%0.2%-6.3%-6.6%-7.1%
EPS (Basic)0.520.04(0.74)(0.90)(1.02)
EPS (Diluted)0.520.04(0.74)(0.90)(1.02)
Weighted Avg Shares350M350M350.5M351.8M353.8M
Weighted Avg Shares (Diluted)350M350M350.5M351.8M353.8M

Bausch + Lomb Corporation

NYSE:BLCO

Intrinsic Alpha fair value

Locked

Current Price

$20.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.